|
|
|
|
Hemcheck's Newsletter - August 2022
|
|
|
In August, we came back after the summer vacation period in July. After the capital raising completed in June, we have been planning the work for the autumn including continued strong focus on our commercial activities, while both adjusting our cost base and evaluating the possibilities of strategic partnerships.
|
After the CE-marking of our products for diagnostic use completed in May, we have gotten even more interested customers and distributors, which have already led to several trial orders. This positive start is something we would like to capitalize on during the coming months. We therefore look forward to the autumn and the potential opportunities that are ahead of us.
|
|
|
|
In this newsletter you can specifically read more about some of our planned commercial activities and developments.
|
|
|
|
Distribution agreement signed for the Spanish market
|
|
In July Hemcheck signed a distributor agreement with SDO Medical regarding the Spanish market. The agreement entails an initial evaluation period of 6 months and a requirement for a first order.
|
|
SDO Medical has shown strong interest and has many customer contacts in the Spanish market. They will focus on customers in both diagnostic and non-diagnostic use.
|
|
|
|
|
Hemcheck receives additional order from its French distributor
|
Hemcheck has received an additional order from its French distributor Eurobio Scientific. The order is of lower economic value but the third in a relatively short time and includes all types of tests. Eurobio Scientific has stated that they see large potential in the products and will soon carry out major sales and marketing activities in the country.
|
|
|
|
|
Interim report Q2 2022 now available
|
|
|
Hemcheck released the interim report for the second quarter of 2022 on August 30.
|
|
|
|
More about Hemchecks commercial activities in the autumn of 2022
|
|
|
We have a lot of commercial activities planned for the autumn, with focus on fairs and trade shows as well as working towards end customers especially with our distributors to achieve an increased number of orders. Below you can find some more information about some of the planned activities:
|
Labdays is a trade fair for laboratory professionals like bioanalysts and physicians in hospitals, research and industry with exhibition, seminars, panel debates and networking. Hemcheck will attend the meeting as visitors with the primary aim to get in contact with potential customers and distributors in Denmark.
|
The conference is focused on open and endovascular aortic repair with focus on new technologies and is designed for cardiovascular surgeons, cardiologists, radiologists, anesthesiologists, perfusionists and nurses. The structure of the meeting will include live and live-in-a-box cases alongside lectures and videos from masters of the field. Hemcheck will attend the meeting as exhibitor together with an Italian distributor, Levi Biotech, with the aim to showcase our concept and get in contact with hospitals willing to test and implement our diagnostic solution.
|
The meeting is gathering biomedical analysts, chemists, laboratory doctors, laboratory managers in clinical chemistry from all over Sweden. Apart from the exhibition the meeting also includes lectures, seminars and poster exhibitions. Hemcheck will attend the meeting as an exhibitor together with our Nordic distributor, Vingmed, with the aim to present our concept and get in contact with hospitals in the Nordic countries willing to test and implement our technology.
|
The yearly congress of SFAR (French Society of Anesthesia and Resuscitation) gathers 6,000 participants and is based on the quality of more than 700 presentations (and nearly 600 e-posters), 200 scientific sessions and 27 practical workshops, live debates etc addressing all the themes of anesthesia, resuscitation and perioperative medicine. Hemcheck will attend the meeting as an exhibitor together with our distributor in France, Eurobio Scientific, with the aim to showcase our concept and get in contact with hospitals willing to test and implement our solution in routine work.
|
The focus of the conference is the clinical progress of near-patient laboratory diagnostics in hospitals as well as in ambulatories, private practices and also in the homecare sector. The meeting gathers 400 POCT representatives, scientists, physicians and medical staff from practices and clinics, mainly from German speaking countries (DACH region). Hemcheck will take part in the meeting as an exhibitor and as speaker in the scientific programme with a short presentation of the results of the study performed at the University Hospital Centre in Zagreb (KBC) by Ivana Baršić Lapić. Our aim is to display our concept and get in contact with hospitals in the DACH countries willing to test and implement our technology as well as potential distributors in the same region.
|
Additional activities are planned for October and November such as attending UKMedLab22 in London, and MEDICA in Düsseldorf.
|
We hope that we will have a successful autumn and that the commercial activities will translate into increased sales.
|
Peter Andersson, Sales & Marketing, Deputy CEO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
